A More Competitive Europe Through Smarter Health Decisions

Across Europe, a new chapter in Health Technology Assessment is taking shape.

Member States are now working together to assess the clinical value of new medicines through Joint Clinical Assessments under the EU HTA Regulation.

One year into its application, the conversation is moving from theory to reality. What does implementation actually look like? How are the first Joint Clinical Assessments being carried out? And why does this matter for patients, health systems and Europe’s innovation environment?

In this episode of Break the Bubble, Incisive Health Senior Counsel Hans Martens sits down with Maya Matthews, Head of the HTA Unit at DG SANTE.

Together, they explore how the first phase of the Regulation is taking shape, starting with oncology medicines and gene therapies. They discuss how Joint Clinical Assessments are aligned with EMA marketing authorizations, how patients and clinicians are now involved in shaping the assessment process, and how cooperation at EU level aims to reduce duplication while increasing transparency and quality.

What could this mean for innovation, for trust in decision-making and for access to new medicines across Europe?